BioNexus Gene Lab (BGLC) Receivables - Net (2020 - 2026)

BioNexus Gene Lab has disclosed Receivables - Net across 7 years of filings, most recently posting $864874.0 for Q2 2026.

• In Q2 2026, Receivables - Net fell 53.3% year-over-year to $864874.0; the TTM figure through Jun 2026 stood at $864874.0 (down 53.3% YoY), while the FY2025 annual figure was $1.2 million, down 36.14% from the prior year.
• Receivables - Net came in at $864874.0 for Q2 2026 at BioNexus Gene Lab, down from $958763.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $3.0 million in Q1 2022 to a low of $799674.0 in Q4 2023.
• Average Receivables - Net over 5 years is $1.7 million, with a median of $1.5 million recorded in 2025.
• Year-over-year, Receivables - Net sank 72.12% in 2023 and jumped 136.9% in 2024.
• Over 5 years, Receivables - Net stood at $2.9 million in 2022, then slumped by 72.12% to $799674.0 in 2023, then soared by 136.9% to $1.9 million in 2024, then plunged by 36.14% to $1.2 million in 2025, then dropped by 28.52% to $864874.0 in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $864874.0 in Q2 2026, $958763.0 in Q1 2026, and $1.2 million in Q4 2025.